Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for testosterone
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on testosterone or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on testosterone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Testosterone for low sexual desire in nonsurgically postmenopausal women Testosterone for low sexual desire in nonsurgically postmenopausal women Testosterone for low sexual desire in nonsurgically postmenopausal women Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Testosterone for low sexual desire in nonsurgically postmenopausal women. Lansdale: HAYES, Inc (...) .. Directory Publication. 2013 Authors' conclusions Endogenous androgens such as testosterone are thought to play a role in the regulation of sexual desire, and the goal of testosterone therapy for nonsurgically postmenopausal women is to increase sexual desire. Final publication URL The report may be purchased from: Indexing Status Subject indexing assigned by CRD MeSH Females; Libido; Postmenopause; Sexual Dysfunctions, Psychological; Testosterone Language Published English Country of organisation United
Medicalization of aging and the testosterone deficiency syndrome Servicio Navarro de Salud / Osasunbidea Plaza de la Paz, s/n - 31002 Pamplona T 848429047 - F 848429010 email@example.com Drug and Therapeutics Bulletin of Navarre. Spain abstract n Objective: to carry out a critical appraisal of the Testosterone Deficit Syndrome (TDS), also known as low testosterone or T-low, its diagnosis and management. Materials and methods: a bibliographic search was carried out in the TRIP (...) database and PubMed with the following key words: “testosterone deficiency”, “late-onset hypogonadism”, “male andropause” and “androgen deficiency in aging males” filtered by the type of study (clinical practice guidelines, systematic reviews, meta-analyses or clinical trials). Information on consumption and sales was obtained from invoiced prescriptions in Navarre from 2001 upto 2011. Results: many of the signs and symptoms that define this syndrome overlap with those produced by other health problems
What Is Andropause? Is Testosterone Supplementation the Answer in Older Men? What Is Andropause? Is Testosterone Supplementation the Answer in Older Men? – Clinical Correlations Search What Is Andropause? Is Testosterone Supplementation the Answer in Older Men? September 20, 2012 5 min read By Kylie Birnbaum Faculty Peer Reviewed Women have long bemoaned menopause and its physiological, psychological, and sexual effects. Fortunately, hormone replacement therapy has provided relief (...) for symptomatic women. Less attention is paid to men, who also experience declines in their sex hormones. Decreased testosterone may explain many symptoms experienced by elderly men, such as poor sexual function and libido, decreased bone mineral density, fatigue, and decreased muscle mass and strength. Should physicians treat elderly men with testosterone replacement therapy? Late-onset hypogonadism, or “andropause,” is the gradual decline in testosterone levels in aging men. It differs from menopause
Effect of testosterone supplementation with and without a dual 5Î±-reductase inhibitor on fat-free mass in men with suppressed testosterone production: a randomized controlled trial. Steroid 5α-reductase inhibitors are used to treat benign prostatic hyperplasia and androgenic alopecia, but the role of 5α-dihydrotestosterone (DHT) in mediating testosterone's effects on muscle, sexual function, erythropoiesis, and other androgen-dependent processes remains poorly understood.To determine whether (...) testosterone's effects on muscle mass, strength, sexual function, hematocrit level, prostate volume, sebum production, and lipid levels are attenuated when its conversion to DHT is blocked by dutasteride (an inhibitor of 5α-reductase type 1 and 2).The 5α-Reductase Trial was a randomized controlled trial of healthy men aged 18 to 50 years comparing placebo plus testosterone enthanate with dutasteride plus testosterone enanthate from May 2005 through June 2010.Eight treatment groups received 50, 125, 300
Effect of 1 Week of Sleep Restriction on Testosterone Levels in Young Healthy MenFREE 21632481 2011 06 03 2018 11 13 1538-3598 305 21 2011 Jun 01 JAMA JAMA Effect of 1 week of sleep restriction on testosterone levels in young healthy men. 2173-4 10.1001/jama.2011.710 Leproult Rachel R Department of Medicine, University of Chicago, Chicago, Illinois, USA. Van Cauter Eve E eng P60DK-020595 DK NIDDK NIH HHS United States 5R01HL72694-5 HL NHLBI NIH HHS United States M01 RR000055 RR NCRR NIH HHS (...) United States MO1-RR-00055 RR NCRR NIH HHS United States R01 HL072694 HL NHLBI NIH HHS United States P60 DK020595 DK NIDDK NIH HHS United States Journal Article Research Support, N.I.H., Extramural United States JAMA 7501160 0098-7484 3XMK78S47O Testosterone WI4X0X7BPJ Hydrocortisone AIM IM Adult Fatigue Humans Hydrocortisone blood Male Sleep Deprivation physiopathology Testosterone blood deficiency Young Adult 2011 6 3 6 0 2011 6 3 6 0 2011 6 4 6 0 ppublish 21632481 305/21/2173 10.1001/jama.2011.710
Reduction in 24-hour plasma testosterone levels in subjects who showered 15 or 30 minutes after application of testosterone gel. To investigate whether showering, to prevent the involuntary transfer of testosterone to others through skin contact, either 15 or 30 minutes after application of testosterone gel would significantly affect plasma testosterone levels.Prospective 3-way crossover trial.University hospital in the Netherlands.Ten agonadal female-to-male transsexuals who had sex (...) -reassignment surgery at least 3 months earlier.Subjects were randomized to one of three application regimens for testosterone gel 50 mg/day, each lasting 7 days: testosterone application after showering (standard regimen), shower was taken 30 minutes after testosterone application, or shower was taken 15 minutes after testosterone application. Subjects then crossed over to each of the other two application regimens for a total of 21 days of study participation.On day 7 of each application regimen, mean
Incomplete testosterone suppression in prostate cancer. 21067409 2010 11 30 2013 11 21 1533-4406 363 20 2010 Nov 11 The New England journal of medicine N. Engl. J. Med. Incomplete testosterone suppression in prostate cancer. 1976 10.1056/NEJMc1010187 Crawford E David ED Rove Kyle O KO eng Letter United States N Engl J Med 0255562 0028-4793 0 Androgen Antagonists 33515-09-2 Gonadotropin-Releasing Hormone 3XMK78S47O Testosterone AIM IM Androgen Antagonists pharmacology therapeutic use (...) Gonadotropin-Releasing Hormone agonists antagonists & inhibitors Humans Male Prostatic Neoplasms blood drug therapy mortality Testosterone blood 2010 11 12 6 0 2010 11 12 6 0 2010 12 14 6 0 ppublish 21067409 10.1056/NEJMc1010187
Fortesta (testosterone) Gel for topical use Drug Approval Package: Fortesta (testosterone) NDA #021463 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Fortesta (testosterone) Gel for topical use, 10 mg of testosterone per pump actuation Company: Endo Pharmaceuticals, Inc. Application No.: 021463 Approval Date: 12/29/2010 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF
Adverse events associated with testosterone administration. Testosterone supplementation has been shown to increase muscle mass and strength in healthy older men. The safety and efficacy of testosterone treatment in older men who have limitations in mobility have not been studied.Community-dwelling men, 65 years of age or older, with limitations in mobility and a total serum testosterone level of 100 to 350 ng per deciliter (3.5 to 12.1 nmol per liter) or a free serum testosterone level of less (...) than 50 pg per milliliter (173 pmol per liter) were randomly assigned to receive placebo gel or testosterone gel, to be applied daily for 6 months. Adverse events were categorized with the use of the Medical Dictionary for Regulatory Activities classification. The data and safety monitoring board recommended that the trial be discontinued early because there was a significantly higher rate of adverse cardiovascular events in the testosterone group than in the placebo group.A total of 209 men (mean
Effects of testosterone replacement in middle-aged men with dysthymia: a randomized, placebo-controlled clinical trial Mid-life onset male dysthymic disorder (DD) seems to be a distinct clinical condition with limited therapeutic options. Testosterone replacement is mood-enhancing and has been proposed as an antidepressant therapy, though this strategy has received limited systematic study. We therefore conducted a six-week double-blind placebo-controlled clinical trial in 23 men with DD (...) and with low or low-normal testosterone (T) level (i.e, screening total serum testosterone <350 ng/dL). Enrolled men were randomized to receive intramuscular injections of 200 mg of testosterone cypionate or placebo every 10 days. The primary outcome measures were the Clinical Global Impression (CGI) improvement score and the 21-item Hamilton Depression Rating Scale (HDRS) score.Twenty-three patients were randomized. The mean (SD) age of the enrolled patients was 50.6 (7.0) years and that of total
Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.
Testosterone and depression: systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.
Testosterone for low sexual desire in premenopausal women Testosterone for low sexual desire in premenopausal women Testosterone for low sexual desire in premenopausal women Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Report may be purchased from . Citation Testosterone for low sexual desire in premenopausal women . Lansdale: HAYES, Inc.. 2009 Authors' objectives (...) Administration of exogenous testosterone has been investigated as a treatment for low sexual desire in women. Endogenous androgens, produced in women by the ovaries, adrenal glands, and in peripheral tissue, are thought to play a role in the regulation of sexual desire. Although the precise relationship between testosterone levels and sexual desire in women is not clear, the goal of testosterone therapy is to increase sexual desire. Project page URL Indexing Status Subject indexing assigned by CRD MeSH
Testosterone for low sexual desire in surgically postmenopausal women Testosterone for low sexual desire in surgically postmenopausal women Testosterone for low sexual desire in surgically postmenopausal women Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Report may be purchased from . Citation Testosterone for low sexual desire in surgically postmenopausal women (...) . Lansdale: HAYES, Inc.. 2009 Authors' objectives Administration of exogenous testosterone has been investigated as a treatment for low sexual desire in women. Endogenous androgens, produced in women by the ovaries, adrenal glands, and peripheral tissue, are thought to play a role in the regulation of sexual desire. In women in whom both ovaries are removed (bilateral oophorectomy), testosterone levels drop substantially and sexual desire may be reduced. Although the precise relationship between
Short-term testosterone augmentation in male schizophrenics: a randomized, double-blind, placebo-controlled trial Although there are few studies on the treatment of schizophrenia with testosterone, several indirect findings have suggested testosterone as a possible treatment modality for schizophrenia. To explore the therapeutic effect of testosterone augmentation of antipsychotic medication on symptoms in male patients with schizophrenia, the authors performed a placebo-controlled, double (...) -blind trial on 30 schizophrenic men, using either 5 g of 1% testosterone gel (Testogel; Besins Iscovesco, Paris, France) or a placebo added to a fixed dosage of antipsychotic medication over a period of 4 weeks with a 2-week washout period. In addition, to get additional information about the involvement of these reproductive hormones after testosterone augmentation, the authors evaluated several hormones such as total testosterone, free testosterone, dehydroepiandrosterone sulfate, estradiol
Testosterone for low libido in postmenopausal women not taking estrogen. The efficacy and safety of testosterone treatment for hypoactive sexual desire disorder in postmenopausal women not receiving estrogen therapy are unknown.We conducted a double-blind, placebo-controlled, 52-week trial in which 814 women with hypoactive sexual desire disorder were randomly assigned to receive a patch delivering 150 or 300 microg of testosterone per day or placebo. Efficacy was measured to week 24; safety (...) was evaluated over a period of 52 weeks, with a subgroup of participants followed for an additional year. The primary end point was the change from baseline to week 24 in the 4-week frequency of satisfying sexual episodes.At 24 weeks, the increase in the 4-week frequency of satisfying sexual episodes was significantly greater in the group receiving 300 microg of testosterone per day than in the placebo group (an increase of 2.1 episodes vs. 0.7, P<0.001) but not in the group receiving 150 microg per day
Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. Serum testosterone levels decline significantly with aging. Testosterone supplementation to older men might beneficially affect the aging processes.To investigate the effect of testosterone supplementation on functional mobility, cognitive function, bone mineral density, body composition, plasma lipids, quality of life, and safety parameters in older men (...) with low normal testosterone levels.Double-blind, randomized, placebo-controlled trial of 237 healthy men between the ages of 60 and 80 years with a testosterone level lower than 13.7 nmol/L conducted from January 2004 to April 2005 at a university medical center in the Netherlands.Participants were randomly assigned to receive 80 mg of testosterone undecenoate or a matching placebo twice daily for 6 months.Functional mobility (Stanford Health Assessment Questionnaire, timed get up and go test
Testosterone for schizophrenia. Recently, sex hormones such as estrogens and testosterone or its derivatives have been the focus of interest for treatment of persistent symptoms associated with schizophrenia.To review the effects of dehydroepiandrosterone (DHEA)/testosterone as adjunctive therapy to standard antipsychotic drugs.We searched the Cochrane Schizophrenia Group Trials Register (January 2007).We included all clinical randomised trials comparing DHEA/testosterone plus standard